About BioCardia

We are a clinical-stage regenerative medicine company.

Our Mission: To bring to market comprehensive cell therapy solutions for the treatment of cardiovascular diseases with large unmet medical needs.

Our Pipeline: Our lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - heart failure that develops after a heart attack and chronic myocardial ischemia.

Our second therapeutic candidate is the investigational CardiALLO™  Cell Therapy System, an allogeneic culture expanded "off the shelf" cell therapy derived from donor bone marrow cells that have been identified to meet specified criteria. This therapy has the potential to be advanced for many clinical indications including heart failure.



News

28 Oct

Cardiology Today

Ongoing trial assessing novel assay to determine response to cardiac regenerative therapy
Read More
11 May

University of Minnesota

Investigational Therapy Exploring Treatment of Heart Failure Seeks to Stimulate Body’s Natural Healing Response
Read More
31 Jan

BioWorld Med Tech

Biocardia wins IDE for cell therapy as treatment for angina
Read More
03 Oct

BioWorld Med Tech

Biocardia presses on with Cardiamp pivotal trial to treat patients with heart failure
Read More
26 May

Med Latest

BioCardia® Helix Results in Higher Stem Cell Retention in Myocardium
Read More
24 May

Fox 47

UW Health trial involves injecting stem cells into patients with heart failure
Read More

press releases

01 Jul
2020 BioCardia Announces Activation of Pivotal Trial Studying CardiAMP Cell Therapy Trial to Treat Chronic Myocardial Ischemia
29 Jun
2020 BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era
17 Jun
2020 BioCardia Announces Pricing of $10.0 Million Public Offering
15 May
2020 BioCardia Reports First Quarter 2020 Financial Results and Business Highlights
05 May
2020 BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure
30 Apr
2020 BioCardia Announces FDA-Recommended Modifications to Primary Endpoint for CardiAMP Cell Therapy Heart Failure Trial to Support Marketing Approval
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS